|
1
|
Steliarova-Foucher E, O’Callaghan M,
Ferlay J, et al: European Cancer Observatory: Cancer Incidence,
Mortality, Prevalence and Survival in Europe. Version 1.0.
September. 2012, European Network of Cancer Registries,
International Agency for Research on Cancer. http://eco.iarc.fr.
Accessed June 18, 2013
|
|
2
|
Coleman RE: Clinical features of
metastatic bone disease and risk of skeletal morbidity. Clin Cancer
Res. 12:6243s–6249s. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galasko C: The anatomy and pathways of
skeletal metastases. Bone Metastases. Weiss L and Gilbert A: GK
Hall; Boston: pp. 49–63. 1981
|
|
4
|
Mok TS: Personalized medicine in lung
cancer: what we need to know. Nat Rev Clin Oncol. 8:661–668. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brodowicz T, O’Byrne K and Manegold C:
Bone matters in lung cancer. Ann Oncol. 23:2215–2222. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosen LS, Gordon D, Tchekmedyian NS, et
al: Long-term efficacy and safety of zoledronic acid in the
treatment of skeletal metastases in patients with nonsmall cell
lung carcinoma and other solid tumors: a randomized, phase III,
double-blind, placebo-controlled trial. Cancer. 100:2613–2621.
2004. View Article : Google Scholar
|
|
7
|
Costa L, Badia X, Chow E, Lipton A and
Wardley A: Impact of skeletal complications on patients’ quality of
life, mobility, and functional independence. Support Care Cancer.
16:879–889. 2008.
|
|
8
|
Mercadante S: Malignant bone pain:
pathophysiology and treatment. Pain. 69:1–18. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Loblaw DA, Wu JS, Kirkbride P, et al: Pain
flare in patients with bone metastases after palliative
radiotherapy - a nested randomized control trial. Support Care
Cancer. 15:451–455. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Coleman RE: Skeletal complications of
malignancy. Cancer. 80(Suppl 8): 1588–1594. 1997. View Article : Google Scholar
|
|
11
|
National Collaborating Centre for Cancer
(UK). Opioids in palliative care: safe and effective prescribing of
strong opioids for pain in palliative care of adults. Full
guideline. May;2012.PubMed/NCBI
|
|
12
|
Loblaw DA, Perry J, Chambers A and
Laperriere NJ: Systematic review of the diagnosis and management of
malignant extradural spinal cord compression: the Cancer Care
Ontario Practice Guidelines Initiative’s Neuro-Oncology Disease
Site Group. J Clin Oncol. 23:2028–2037. 2005.
|
|
13
|
Katzer A, Meenen NM, Grabbe F and Rueger
JM: Surgery of skeletal metastases. Arch Orthop Trauma Surg.
122:251–258. 2002. View Article : Google Scholar
|
|
14
|
Body JJ, Chevalier P, Gunther O, Hechmati
G and Lamotte M: The economic burden associated with
skeletal-related events in patients with bone metastases secondary
to solid tumors in Belgium. J Med Econ. 16:539–546. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Delea T, Langer C, McKiernan J, et al: The
cost of treatment of skeletal-related events in patients with bone
metastases from lung cancer. Oncology. 67:390–396. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Delea T, McKiernan J, Brandman J, et al:
Retrospective study of the effect of skeletal complications on
total medical care costs in patients with bone metastases of breast
cancer seen in typical clinical practice. J Support Oncol.
4:341–347. 2006.PubMed/NCBI
|
|
17
|
Pockett RD, Castellano D, McEwan P,
Oglesby A, Barber BL and Chung K: The hospital burden of disease
associated with bone metastases and skeletal-related events in
patients with breast cancer, lung cancer, or prostate cancer in
Spain. Eur J Cancer Care (Engl). 19:755–760. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schulman KL and Kohles J: Economic burden
of metastatic bone disease in the U.S. Cancer. 109:2334–2342. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Decroisette C, Monnet I, Berard H, et al:
Epidemiology and treatment costs of bone metastases from lung
cancer: a French prospective, observational, multicenter study
(GFPC 0601). J Thorac Oncol. 6:576–582. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoefeler H, Duran I, Hechmati G, et al:
Health resource utilization associated with skeletal-related events
in patients with bone metastases: results from a multinational
retrospective - prospective observational study - a cohort from 4
European countries. J Bone Oncol. (In press).
|
|
21
|
Hechmati G, Cure S, Gouepo A, et al: Cost
of skeletal-related events in European patients with solid tumours
and bone metastases: data from a prospective multinational
observational study. J Med Econ. 16:691–700. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lüftner D, Lorusso V, Duran I, et al:
Health resource utilization associated with skeletal-related events
in patients with advanced breast cancer: results from a
prospective, multinational observational study. Submitted for
publication. 2013.
|
|
23
|
Hoefeler H, Duran I, Hechmati G, et al:
Health resource utilization (HRU) associated with skeletal-related
events (SREs) by tumour type in patients with bone
metastases/lesions: European analysis of a prospective
multinational observational study. Eur J Cancer. 47:S262–S263.
2011.
|
|
24
|
Lüftner D, Lorusso V, Duran I, et al:
Health resource utilization (HRU) associated with skeletal-related
events (SREs) in advanced breast cancer patients with bone
metastases: results from a prospective multinational observational
study. Cancer Res. 71(24 Suppl): abstract P4-16-09. 2011.
|
|
25
|
Royal College of Radiologists. Single
fraction radiotherapy for bone metastases. http://www.rcr.ac.uk/docs/oncology/pdf/bonemetsreport.pdf.
Accessed June 27, 2013
|
|
26
|
Williams MV, Summers ET, Drinkwater K and
Barrett A: Radiotherapy dose fractionation, access and waiting
times in the countries of the UK in 2005. Clin Oncol (R Coll
Radiol). 19:273–286. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Casas A, Lebret T, Cavo M, et al: Insights
into the management of bone metastases: a comprehensive European
survey. Support Care Cancer. 20:S882012.
|
|
28
|
Calderone R, Nimako K, Leary A, Popat S
and O’Brien ME: Under usage of zoledronic acid in non-small cell
lung cancer patients with metastatic bone disease - a short
communication. Eur J Cancer. 47:1603–1605. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Woll PJ, Flinois A, Schoen P, Shepherd S
and Haynes I: Insights into the management of bone metastases in
patients with lung cancer: A comprehensive European survey. Eur J
Cancer. 49:abstract 3473. 2013.
|
